Drug Type Monoclonal antibody |
Synonyms ASD 141, ASD 141(Ascendo Biotechnology), ASD141 + [2] |
Target |
Mechanism CD11b antagonists(integrin subunit alpha M antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Ascendo Biotechnology, Inc.Startup |
Active Organization Ascendo Biotechnology, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Solid Tumor | Phase 1 | TW | Ascendo Biotechnology, Inc.Startup | 29 Aug 2024 |
Neoplasms | Phase 1 | US | Ascendo Biotechnology, Inc.Startup | - |